查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1370957

額顳葉失智症市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、疾病適應症、配銷通路、地區和競爭細分

Frontotemporal Dementia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Disease Indication, By Distribution Channel, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球額顳葉失智症（FTD）市場估值達到2.4136億美元，預計在預測期內強勁成長，預計年複合成長率（CAGR）為6.39%，到2028年預計將達到3.466億美元。額顳葉疾病是一種以大腦額葉或顳葉神經細胞退化為特徵的神經系統疾病。這種疾病包括癡呆、進行性核上性麻痺和原發性進行性失語等多種疾病，顯著影響行為、語言、運動和個性，損害個人進行日常活動的能力。額顳葉疾病，也稱為額顳葉變性，是一類主要影響額葉和顳葉的腦部疾病。這些病症涉及神經細胞的逐漸喪失和癡呆的發展。通常，額顳葉疾病在 40 至 60 歲之間出現，但也可能在 60 歲之後發病。診斷後，額顳葉疾病患者的平均壽命約為 8-10 年。鑑於額顳葉疾病對醫療保健產業的重大影響，預計在預測期內將出現顯著成長。

主要市場促進因素：

  • 1.增加 FTD 藥物開發和資助：由於患者人數不斷增加，非營利組織、疾病倡導團體和私人實體正在積極支持額顳葉變性 (FTD) 藥物的開發。額顳葉退化協會(AFTD)、Bluefield 計畫組織、Tau 聯盟組織、阿茲海默症發現基金會(ADDF) 和CurePSP, Inc. 等著名非營利組織的研究資助計畫在刺激重點研究工作方面發揮了關鍵作用。關於治療額顳葉疾病。這些組織為臨床和臨床前試驗提供支持，旨在測試能夠減緩或阻止 FTD 和其他罕見神經系統疾病進展的新型療法，從而促進市場成長。
市場概況
預測期 2024-2028
2022 年市場規模 24136萬美元
2028 年市場規模 3.466億美元
2023-2028 年年複合成長率 6.39%
成長最快的細分市場 醫院藥房
最大的市場 北美洲
  • 2.贈款和政府資助：贈款和資金提供資源來支持以 FTD 為重點的研究計劃，包括調查疾病的根本機制、確定潛在的藥物靶點以及開發新的治療方法。充足的資金可以增強 FTD 研究對科學家和研究人員的吸引力，促進合作，並促進創新治療策略的探索。贈款和資金還有助於識別和驗證有希望的 FTD 藥物靶點，這對於開發解決該疾病根本原因的治療方法至關重要。
  • 3.失智症盛行率不斷上升：由於失智症盛行率不斷上升，額顳葉疾病治療市場正在不斷成長。失智症包括認知和溝通功能障礙，顯示存在各種潛在疾病，包括大腦異常。由於目標疾病的盛行率不斷上升以及受這些疾病影響的老年人口不斷增加，預計該市場將會擴大。據世界衛生組織稱，全球約有 5,000 萬人患有失智症，每年診斷出約 1,000 萬新病例。這凸顯了該產業的持續發展。記憶喪失、混亂、行為改變和計劃困難等認知缺陷是失智症患者面臨的挑戰，有助於市場成長。
  • 4.政府對研發的投資不斷增加：隨著人們對失智症的普遍認知不斷提高，醫療保健專業人員和公眾對不同類型的失智症（包括 FTD）的了解也越來越多。這可以更好地識別、診斷和管理 FTD 病例。 FTD 的日益普及導致人們越來越有興趣了解其根本原因和機制。這吸引了更多的研究資金，推動了 FTD 特定研究和藥物開發的進步。隨著 FTD 盛行率的升高，需要準確的早期診斷工具來區分 FTD 和其他形式的失智症。對改進診斷技術的需求正在推動 FTD 市場的創新。
  • 5.準確診斷的技術進步：技術進步在推動額顳葉失智症（FTD）市場方面發揮著至關重要的作用。這些進步為 FTD 患者及其照護者提供了更準確的診斷、改進的患者管理、創新的治療方法以及增強的支持系統。正子斷層掃描 (PET) 和功能性磁振造影 (fMRI) 等尖端影像技術可更深入了解 FTD 患者的大腦結構和功能，透過識別腦萎縮和功能障礙的特定模式來幫助早期準確診斷FTD亞型相關。技術進步也有助於識別和驗證與 FTD 相關的生物標記物，從而實現早期檢測、追蹤疾病進展和評估治療效果。遺傳分析技術的進步可以識別與 FTD 相關的基因突變，有助於更好地了解疾病的潛在遺傳基礎。技術工具能夠根據個人的遺傳和分子特徵開發個人化治療方法，有望根據特定的 FTD 亞型和患者特徵來客製化治療方法。遠距醫療和遠端監控技術使醫療保健專業人員能夠評估 FTD 患者的認知和功能狀態，而無需他們前往醫療機構，這對於行動不便或交通受限的患者尤其有利。

主要市場挑戰：

  • 1.神經系統疾病的誤診：額顳葉疾病常被誤診為其他神經或精神疾病，例如憂鬱症、帕金森氏症、阿茲海默症或其他精神疾病。這種誤診可能會導致額顳葉疾病延遲開始適當的治療以及無效甚至有害的治療。準確的診斷對於正確的管理和及時的干涉至關重要。誤診可能會導致不必要的醫療費用、浪費時間和資源，並錯過有效治療的機會。它還可以排除患者參與額顳葉疾病的臨床試驗，從而阻礙標靶治療的開發。
  • 2.藥物試驗失敗率：高

神經系統疾病（包括額顳葉疾病）領域的臨床試驗失敗帶來了重大挑戰，影響了這些疾病治療的成長前景。臨床試驗失敗意味著大量的時間、資源和資金投入，從而延遲了創新療法的推出。失敗的試驗可能會對製藥公司、研究機構和投資者帶來經濟損失，影響未來的研發計畫。失敗的試驗可能會導致研究方向轉變，偏離某些目標或方法，減緩整體進展，並阻礙研究人員追求神經系統疾病的創新治療方法。臨床試驗失敗導致缺乏成功的治療方法，為患者和醫療保健提供者提供的治療選擇較少，從而限制了市場的成長。

主要市場趨勢：

  • 1.更高的藥物批准和先進的治療：治療額顳葉疾病的新藥的批准為患者提供了可能減緩疾病進展、控制症狀和改善生活品質的治療方法。這導致 FTD 患者和醫療保健提供者對治療的需求更高。有效的治療通常伴隨著改進的診斷方法、生物標記和篩檢工具，有助於早期診斷和患者識別。藥物批准引起了媒體的關注，並提高了患者、照護者和公眾的認知，導致更多的人尋求 FTD 的診斷和治療方案。
  • 2. FDA 的孤兒藥開發獎勵措施：美國食品藥物管理局（FDA）提供的孤兒藥開發激勵措施有可能顯著增加額顳葉失智症（FTD）市場的治療需求。孤兒藥旨在治療罕見疾病和病症，包括許多神經退化性疾病，如 FTD。 FDA 為研究孤兒藥的藥物開發商提供一定的經濟激勵，包括降低監管提交和行銷申請的費用。獲得 FDA 批准的孤兒藥將獲得更大的市場獨佔權，為 FTD 治療創造更有利的商業環境。

細分洞見：

藥物類別見解：治療額顳葉疾病的全球市場分為各種藥物類別，包括抗精神病藥物、認知增強劑、中樞神經系統興奮劑、抗憂鬱藥物等。其中，抗憂鬱藥物預計將在預測期內帶來利潤豐厚的機會。抗憂鬱藥物主要用於治療憂鬱症和其他病症，包括心境惡劣、強迫症 (OCD)、焦慮症、神經性疼痛、飲食失調和慢性疼痛等。選擇性血清素再攝取抑制劑（SSRI）已被證明對治療額顳葉疾病有益。

疾病適應症洞察：額顳葉失智症在 2022 年佔額顳葉失智症市場最大的市場佔有率，預計在預測期內將成長。預計原發性進行性失語症在預測期內將表現出最高的年複合成長率。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細目
  • 管道細分（按狀態）
  • 按研究應用分類的管道細分
  • 按地區分類的管道明細
  • 臨床試驗熱圖

第 6 章：全球額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物類別（認知增強劑、抗精神病藥、抗憂鬱劑、中樞神經系統興奮劑和其他藥物類別）
    • 依疾病指徵（額顳葉失智症、原發性進行性失語症及運動障礙）
    • 按配銷通路（醫院藥房、零售藥房和網路藥房）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 7 章：北美額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 8 章：歐洲額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 9 章：亞太地區額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 10 章：南美洲額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲額顳葉失智症市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物類別
    • 按疾病適應症
    • 按配銷通路
    • 按國家/地區
  • MEA：國家分析
    • 南非額顳葉失智症
    • 沙烏地阿拉伯 額顳葉失智症
    • 阿拉伯聯合大公國額顳葉失智症

第 12 章：市場動態

  • 促進要素
  • 挑戰

第 13 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 14 章：全球額顳葉失智症市場：SWOT 分析

第 15 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第16章：競爭格局

  • 商業概覽
  • 服務內容
  • 最近的發展
  • 主要人員
  • SWOT分析
    • Transposon Therapeutics
    • Alector Inc.
    • Denali Therapeutics Inc.
    • Pfizer Inc.
    • Johnson & Johnson Services Inc.
    • Prevail Therapeutics
    • Wave Life Sciences
    • AstraZeneca plc
    • GlaxoSmithKline plc
    • TauRx Pharmaceuticals Ltd.

第 17 章：策略建議

第 18 章：關於我們與免責聲明

簡介目錄
Product Code: 4841

The Global Frontotemporal Dementia (FTD) Market reached a valuation of USD 241.36 Million in 2022 and is poised for robust growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.39% and expected to reach USD 346.60 Million through 2028. Frontotemporal diseases represent a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which encompasses various disorders such as dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly affects behavior, language, movement, and personality, impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a category of brain disorders primarily impacting the frontal and temporal lobes. These conditions involve the progressive loss of nerve cells and the development of dementia. Typically, frontotemporal disorders manifest between the ages of 40 and 60, although onset can occur after the age of 60. Following diagnosis, individuals with frontotemporal disorders have an average life expectancy of approximately 8-10 years. Given its substantial impact on the healthcare sector, frontotemporal disorders are expected to experience significant growth in the forecast period.

Key Market Drivers:

  • 1. Increasing FTD Drug Development and Funding: Non-profit organizations, disease advocacy groups, and private entities are actively supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from prominent non-profit organizations like the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a pivotal role in stimulating research efforts focused on treating frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can slow down or halt the progression of FTD and other rare neurological diseases, contributing to market growth.
Market Overview
Forecast Period2024-2028
Market Size 2022USD 241.36 Million
Market Size 2028USD 346.60 Million
CAGR 2023-20286.39%
Fastest Growing SegmentHospital Pharmacy
Largest MarketNorth America
  • 2. Grants and Government Funding: Grants and funding provide resources to support FTD-focused research initiatives, including investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Adequate funding enhances the attractiveness of FTD research for scientists and researchers, fosters collaboration, and facilitates the exploration of innovative therapeutic strategies. Grants and funding also assist in the identification and validation of promising drug targets for FTD, which is crucial for developing treatments that address the root causes of the disease.
  • 3. Increasing Prevalence of Dementia: The Frontotemporal Disorders Treatment Market is witnessing growth due to the rising prevalence of dementia. Dementia encompasses cognitive and communicative dysfunction, indicative of various underlying conditions, including brain abnormalities. The market is projected to expand due to the growing prevalence of target diseases and a rising geriatric population affected by these conditions. According to the World Health Organization, approximately 50 million individuals worldwide suffer from dementia, with around 10 million new cases diagnosed annually. This underscores the continued development of this sector. Cognitive deficits such as memory loss, confusion, behavioral changes, and planning difficulties are among the challenges faced by individuals with dementia, contributing to market growth.
  • 4. The Rising Investment in Research and Development by Governments: As general awareness about dementia increases, healthcare professionals, and the public are becoming more knowledgeable about different types of dementia, including FTD. This results in better recognition, diagnosis, and management of FTD cases. The growing prevalence of FTD has led to increased interest in understanding its underlying causes and mechanisms. This has attracted more research funding, driving advancements in FTD-specific research and drug development. With a higher prevalence of FTD, there is a need for accurate and early diagnostic tools to distinguish FTD from other forms of dementia. The demand for improved diagnostic technologies is driving innovation in the FTD market.
  • 5. Technological Advancements for Accurate Diagnosis: Technological advancements are playing a crucial role in boosting the Frontotemporal Dementia (FTD) market. These advancements enable more accurate diagnosis, improved patient management, innovative treatments, and enhanced support systems for individuals with FTD and their caregivers. Cutting-edge imaging technologies such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) provide deeper insights into the brain structure and function of individuals with FTD, aiding in early and accurate diagnosis by identifying specific patterns of brain atrophy and dysfunction associated with FTD subtypes. Technological advancements also facilitate the identification and validation of biomarkers associated with FTD, enabling earlier detection, tracking of disease progression, and assessment of treatment efficacy. Advances in genetic analysis techniques allow for the identification of genetic mutations associated with FTD, contributing to a better understanding of the disease's underlying genetic basis. Technological tools enable the development of personalized treatment approaches based on an individual's genetic and molecular profile, holding promise for tailoring therapies to specific FTD subtypes and patient characteristics. Telemedicine and remote monitoring technologies allow healthcare professionals to assess FTD patients' cognitive and functional status without requiring them to visit healthcare facilities, particularly beneficial for patients with mobility or transportation limitations.

Key Market Challenges:

  • 1. Misdiagnosis of Neurological Disorders: Frontotemporal disorders are often misdiagnosed as other neurological or psychiatric conditions such as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric disorders. This misdiagnosis can lead to delayed initiation of appropriate treatment for frontotemporal disorders and ineffective or even harmful treatments. Accurate diagnosis is crucial for proper management and timely intervention. Misdiagnosis can result in unnecessary medical expenses, wasted time and resources, and missed opportunities for effective treatments. It can also exclude patients from participating in clinical trials for frontotemporal disorders, hindering the development of targeted therapies.
  • 2. Drug Trial Failures: The high rate

of clinical trial failures in the field of neurological conditions, including frontotemporal disorders, poses a significant challenge that impacts the growth prospects of treatments for these conditions. Clinical trial failures represent a substantial investment of time, resources, and funding, delaying the availability of innovative treatments. Failed trials can lead to financial losses for pharmaceutical companies, research institutions, and investors, impacting future research and development initiatives. Failed trials can result in a shift in research direction, away from certain targets or approaches, slowing overall progress, and discouraging researchers from pursuing innovative treatment approaches for neurological conditions. The lack of successful treatments resulting from clinical trial failures can limit market growth by offering fewer treatment options for patients and healthcare providers.

Key Market Trends:

  • 1. Higher Drug Approvals and Advanced Treatment: The approval of new drugs for frontotemporal disorders provides patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools, facilitating early diagnosis and patient identification. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public, leading to more individuals seeking diagnosis and treatment options for FTD.
  • 2. Orphan Drug Development Incentives by FDA: The orphan drug development incentives provided by the U.S. Food and Drug Administration (FDA) have the potential to significantly boost the demand for treatments in the Frontotemporal Dementia (FTD) market. Orphan drugs are intended to treat rare diseases and conditions, including many neurodegenerative disorders like FTD. The FDA provides certain financial incentives to drug developers working on orphan drugs, including reduced fees for regulatory submissions and marketing applications. Orphan drugs that receive FDA approval are granted extended market exclusivity, creating a more favorable commercial environment for FTD treatments.

Segmental Insights:

Drug Class Insights: The global market for the treatment of frontotemporal disorders is segmented into various drug classes, including antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to present lucrative opportunities during the forecast period. Antidepressant drugs are primarily used for the management of depressive disorders and other conditions, including dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

Disease Indication Insights: Frontotemporal Dementia accounted for the largest market share in the Frontotemporal Dementia Market in 2022 and is projected to grow during the forecast period. Primary Progressive Aphasia is expected to exhibit the highest compound annual growth rate during the forecast period.

Regional Insights: North America emerged as the dominant player in the Frontotemporal Disorders Treatment Market in 2022, driven by growing awareness, advanced healthcare facilities, and rising income levels. The Asia Pacific region is projected to witness a higher compound annual growth rate (CAGR) during the forecast period, fueled by increasing prevalence of frontotemporal disorders and favorable reimbursement policies.

Key Market Players

  • Transposon Therapeutics
  • Alector Inc.
  • Denali Therapeutics Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

  • Cognitive Enhancers
  • Antipsychotics
  • Antidepressants
  • CNS Stimulants
  • Other Drug Classes

Frontotemporal Dementia Market, By Disease Indication:

  • Frontotemporal Dementia
  • Primary Progressive Aphasia
  • Movement Disorders

Frontotemporal Dementia Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frontotemporal Dementia Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

  • Global Frontotemporal Dementia market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Frontotemporal Dementia Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
    • 6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
    • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map

7. North America Frontotemporal Dementia Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Disease Indication
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Frontotemporal Dementia Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Canada Frontotemporal Dementia Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Mexico Frontotemporal Dementia Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By Distribution Channel

8. Europe Frontotemporal Dementia Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Disease Indication
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Germany Frontotemporal Dementia Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Italy Frontotemporal Dementia Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecasty
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. France Frontotemporal Dementia Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Disease Indication
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Spain Frontotemporal Dementia Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Disease Indication
        • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Frontotemporal Dementia Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Disease Indication
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Frontotemporal Dementia Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. India Frontotemporal Dementia Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Japan Frontotemporal Dementia Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By Distribution Channel
    • 9.3.4. South Korea Frontotemporal Dementia Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Disease Indication
        • 9.3.4.2.3. By Distribution Channel
    • 9.3.5. Australia Frontotemporal Dementia Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Disease Indication
        • 9.3.5.2.3. By Distribution Channel

10. South America Frontotemporal Dementia Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Disease Indication
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Frontotemporal Dementia Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Argentina Frontotemporal Dementia Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. Colombia Frontotemporal Dementia Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Frontotemporal Dementia Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Disease Indication
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Frontotemporal Dementia Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Disease Indication
        • 11.3.1.2.3. By Distribution Channel
    • 11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Disease Indication
        • 11.3.2.2.3. By Distribution Channel
    • 11.3.3. UAE Frontotemporal Dementia Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Disease Indication
        • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Development
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Business Overview
  • 16.2. Service Offerings
  • 16.3. Recent Developments
  • 16.4. Key Personnel
  • 16.5. SWOT Analysis
    • 16.5.1. Transposon Therapeutics
    • 16.5.2. Alector Inc.
    • 16.5.3. Denali Therapeutics Inc.
    • 16.5.4. Pfizer Inc.
    • 16.5.5. Johnson & Johnson Services Inc.
    • 16.5.6. Prevail Therapeutics
    • 16.5.7. Wave Life Sciences
    • 16.5.8. AstraZeneca plc
    • 16.5.9. GlaxoSmithKline plc
    • 16.5.10. TauRx Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer